Humacyte (NASDAQ:HUMA) Downgraded by Piper Sandler to “Underweight”

Humacyte (NASDAQ:HUMAGet Rating) was downgraded by Piper Sandler from an “overweight” rating to an “underweight” rating in a report released on Sunday, The Fly reports.

Separately, Zacks Investment Research lowered shares of Humacyte from a “buy” rating to a “hold” rating in a research note on Saturday, April 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. Based on data from, the stock presently has an average rating of “Hold” and a consensus price target of $13.65.

NASDAQ HUMA traded up $0.33 on Friday, reaching $5.37. 534,060 shares of the company’s stock traded hands, compared to its average volume of 315,771. The company has a quick ratio of 20.75, a current ratio of 20.75 and a debt-to-equity ratio of 0.40. The stock has a 50-day simple moving average of $6.60 and a 200 day simple moving average of $7.33. Humacyte has a 12 month low of $4.37 and a 12 month high of $17.45.

Humacyte (NASDAQ:HUMAGet Rating) last posted its quarterly earnings results on Tuesday, March 29th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.03). The company had revenue of $0.18 million during the quarter, compared to analyst estimates of $0.26 million. As a group, analysts expect that Humacyte will post -0.85 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUMA. Penserra Capital Management LLC bought a new stake in shares of Humacyte during the 4th quarter valued at about $25,000. Citigroup Inc. bought a new stake in Humacyte during the third quarter valued at about $47,000. Dixon Hughes Goodman Wealth Advisors LLC bought a new stake in Humacyte during the first quarter valued at about $48,000. Bank of America Corp DE grew its holdings in Humacyte by 96.7% during the fourth quarter. Bank of America Corp DE now owns 6,887 shares of the company’s stock valued at $51,000 after purchasing an additional 3,385 shares during the period. Finally, Teacher Retirement System of Texas bought a new stake in Humacyte during the fourth quarter valued at about $73,000. 9.25% of the stock is currently owned by hedge funds and other institutional investors.

About Humacyte (Get Rating)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).

Featured Stories

The Fly logo

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with's FREE daily email newsletter.